Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy and Safety of Oral Roflumilast in Treatment of Moderate to Severe Psoriasis: a Pilot Study

NCT07233291 is registered in ClinicalTrials.gov with Ahmed Ibrahim as lead sponsor.

NCT NCT07233291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy and Safety of Oral Roflumilast in Treatment of Moderate to Severe Psoriasis: a Pilot Study
Lead sponsor
Ahmed Ibrahim
Phase
Phase 2
Overall status
Recruiting
Start date
August 20, 2025
Completion date
February 28, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis (pso)